Shopping Cart 0
Cart Subtotal
USD 0

Portola Pharmaceuticals Inc (PTLA) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 750
  • Details
  • Table Of Content
  • Licence Rights
  • Section Purchase
  • Products and Companies

Details

Summary

Portola Pharmaceuticals Inc (Portola Pharmaceuticals) is a biopharmaceutical company which conducts research to develop therapeutics in the areas of thrombosis, other hematologic disorders and inflammation. The company's products portfolio include Betrixaban, an oral once-daily Factor Xa inhibitor anticoagulant that inhibits the activity of Factor Xa; andexanet alfa, a recombinant protein designed to reverse anticoagulant activity of both direct and indirect Factor Xa inhibitors; and cerdulatinib, an oral, dual Syk-JAK inhibitor in development to treat hematologic cancers. Portola Pharmaceuticals provides compounds using biomarker and genetic approaches for clinical, regulatory and commercial purpose of life-saving therapies therapies. The company works in collaboration with other pharmaceutical and biotechnology companies for the clinical development of its lead candidates. Portola Pharmaceuticals is headquartered in South San Francisco, California, the US.

Portola Pharmaceuticals Inc (PTLA)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deal Details 12

Private Equity 12

Healthcare Royalty Partners Acquires AndexXa from Portola Pharma 12

Partnerships 13

Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 13

Portola Pharma Enters into Co-Development Agreement with Ora for PRT2761 14

Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 15

Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 16

Aciex Amends Research Agreement With Portola Pharma 17

Portola Pharma Expand Agreement with Lee's Pharma 18

Licensing Agreements 19

Portola Pharma Enters into Licensing Agreement with SRX Cardio 19

Dermavant Sciences Enters into Licensing Agreement with Portola Pharma 20

Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 21

Equity Offering 23

Portola Pharma Raises USD401.6 Million in Public Offering of Shares 23

Portola Pharma Prices Public Offering of Shares for USD150 Million 25

Portola Pharma Prices Public Offering of Shares for USD100 Million 27

Portola Pharma Raises USD185.3 Million in Public Offering of Shares 29

Portola Pharma Completes Public Offering Of Shares For USD 106 Million 31

Portola Pharma Completes IPO For USD 140 Million 32

Portola Pharmaceuticals Inc-Key Competitors 34

Portola Pharmaceuticals Inc-Key Employees 35

Portola Pharmaceuticals Inc-Locations And Subsidiaries 36

Head Office 36

Recent Developments 37

Financial Announcements 37

Nov 07, 2018: Portola Pharmaceuticals reports third quarter 2018 financial results and provides corporate update 37

Aug 09, 2018: Portola Pharmaceuticals reports second quarter 2018 financial results and provides corporate update 39

May 09, 2018: Portola Pharmaceuticals Reports First Quarter 2018 Financial Results and Provides Corporate Update 40

Feb 28, 2018: Portola Pharmaceuticals Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Corporate Update 42

Nov 06, 2017: Portola Pharmaceuticals Reports Third Quarter 2017 Financial Results and Provides Corporate Update 44

Aug 09, 2017: Portola Pharmaceuticals Reports Second Quarter 2017 Financial Results and Provides Corporate Update 45

May 08, 2017: Portola Pharmaceuticals Reports First Quarter 2017 Financial Results and Provides Corporate Update 46

Feb 28, 2017: Portola Pharmaceuticals Reports Fourth Quarter and Year-End 2016 Financial Results and Provides Corporate Update 47

Corporate Communications 49

Sep 20, 2018: Portola Pharmaceuticals appoints Scott Garland President and Chief Executive Officer 49

Sep 07, 2018: Portola Pharmaceuticals announces resignation of Tao Fu as chief commercial officer 50

Aug 09, 2018: Portola Pharmaceuticals appoints Ernie Meyer as executive vice president and chief human resources officer 51

Jun 25, 2018: Portola Pharmaceuticals Names Glenn Brame as Senior Vice President of Technical Operations 52

Jun 04, 2018: Portola Pharmaceuticals Announces Retirement of CEO Bill Lis in 2018 53

Mar 12, 2018: Portola Pharmaceuticals Appoints Biotech Legal Veteran John Moriarty as Executive Vice President and General Counsel 54

Nov 06, 2017: Portola Pharmaceuticals Appoints Industry Veteran John H. Lawrence, M.D., as Senior Vice President and Chief Medical Officer 55

Product News 56

11/30/2017: Portola Pharmaceuticals to Present New Data on Cerdulatinib at the 59th American Society of Hematology (ASH) Annual Meeting 56

Product Approvals 57

Sep 25, 2018: Portola Pharmaceuticals receives FDA Orphan Drug Designation for Cerdulatinib, an oral Syk/JAK inhibitor for the treatment of Peripheral T-Cell Lymphoma 57

Clinical Trials 58

Jun 04, 2018: New Interim Phase 2a Study Results Demonstrate Broad Clinical Activity of Portola Pharmaceuticals' Oral SYK/JAK Inhibitor Cerdulatinib 58

Apr 25, 2018: Portola Pharmaceuticals to Present New Interim Phase 2 Data for Cerdulatinib at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting 60

Jun 23, 2017: European Hematology Association: Two is better than one: The Dual SYK/JAK Inhibitor Cerdulatinib Demonstrates Rapid Tumor Responses in a Phase 2 Study for Relapsed/Refractory NHL 61

Jun 15, 2017: Portola Pharmaceuticals Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma 62

May 18, 2017: Portola Pharmaceuticals Announces Phase 2a Safety and Efficacy Cerdulatinib Data to be Presented at the European Hematology Association 63

May 09, 2017: Portola Pharmaceuticals Announces Cerdulatinib Data to be Presented at the International Conference on Malignant Lymphoma 64

Other Significant Developments 65

Oct 09, 2018: Portola Pharmaceuticals Supports 2018 World Thrombosis Day Campaign to Raise Awareness of Blood Clots as an Urgent and Growing Health Crisis 65

Appendix 66

Methodology 66

About GlobalData 66

Contact Us 66

Disclaimer 66


List Of Figure

List of Figures

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Portola Pharmaceuticals Inc, Deals By Therapy Area, 2012 to YTD 2018 9

Portola Pharmaceuticals Inc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Healthcare Royalty Partners Acquires AndexXa from Portola Pharma 12

Bayer Healthcare Pharma Enters into Agreement with Portola Pharma 13

Portola Pharma Enters into Co-Development Agreement with Ora for PRT2761 14

Portola Pharma Enters into Expanded Agreement with Daiichi Sankyo 15

Portola Pharma Enters into Agreement with Bayer and Janssen Pharma 16

Aciex Amends Research Agreement With Portola Pharma 17

Portola Pharma Expand Agreement with Lee's Pharma 18

Portola Pharma Enters into Licensing Agreement with SRX Cardio 19

Dermavant Sciences Enters into Licensing Agreement with Portola Pharma 20

Bristol-Myers Squibb and Pfizer Enter into Licensing Agreement with Portola Pharma 21

Portola Pharma Raises USD401.6 Million in Public Offering of Shares 23

Portola Pharma Prices Public Offering of Shares for USD150 Million 25

Portola Pharma Prices Public Offering of Shares for USD100 Million 27

Portola Pharma Raises USD185.3 Million in Public Offering of Shares 29

Portola Pharma Completes Public Offering Of Shares For USD 106 Million 31

Portola Pharma Completes IPO For USD 140 Million 32

Portola Pharmaceuticals Inc, Key Competitors 34

Portola Pharmaceuticals Inc, Key Employees 35

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

Products and Companies

Products

Portola Pharmaceuticals Inc, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.